STOCKS TELEGRAPH

Tag: NASD:OMER

  • Omeros (OMER) Stock Rises After Reporting Third-Quarter Results

    Omeros (OMER) Stock Rises After Reporting Third-Quarter Results

    Following the release of its Q3 financial data, Omeros Corporation (NASDAQ: OMER) saw a significant increase in the price of its shares on the US stock charts. OMER stock surged 49.64% to $6.27 per share as of the most recent check. Despite persistent difficulties, this significant rise follows a rather strong financial performance.

    Profitability and Losses

    Compared to the $37.8 million loss, or $0.60 per share, recorded during the same period in 2023, Omeros’ Q3 2024 net loss of $32.2 million, or $0.56 per share, was an improvement. Significant costs were made by the firm throughout the year, including a $21.2 million payment for the buyback of debt associated with term loans and a $18.4 million charge for the supply of the therapeutic ingredient narsoplimab. At the same time, Omeros paid $1.9 million in term loan transaction expenses.

    Development of Narsoplimab Progress

    In a noteworthy move, Omeros and the FDA met well in September to talk about the biologics license application (BLA) for narsoplimab. The meeting yielded minor feedback on the statistical analysis plan for the primary endpoint, which involves comparing patient survival in a pivotal trial to an external registry.

    Omeros promptly revised and resubmitted the plan, expecting an imminent response from the FDA. Should the revised plan align with FDA expectations, the company intends to proceed with efficacy analyses, which will be integral to the resubmission of the BLA.

    Plans for European Approval and Future Developments

    In addition, Omeros is getting ready to submit the narsoplimab marketing authorization application (MAA) to the European Union in the first half of 2025. In addition, discussions with the FDA and European regulators in September and October focused on the Phase 3 program for zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH).

    Both agencies endorsed the design of the proposed studies, the dose-finding strategy, and other elements of the development plan. With regulatory guidance in place, Omeros is on track to initiate Phase 3 enrollment for zaltenibart in early 2025.

  • Royalty Deal Drove After-Hour Rally In Omeros (OMER) Stock

    Royalty Deal Drove After-Hour Rally In Omeros (OMER) Stock

    Omeros Corporation (NASDAQ: OMER) shares continued their ascent on the US stock market, persisting even after the close of business yesterday. Omeros’ stock witnessed an impressive surge of 8.82%, reaching $3.7 during the extended trading session. This increase followed a 4.94% rise in the regular session, concluding at $3.40. The surge in OMER stock was triggered by the execution of a noteworthy royalty purchase agreement by the company.

    Today, Omeros (OMER) revealed the transfer of an expanded stake in particular royalty proceeds tied to the net revenue from OMIDRIA in the United States to DRI Healthcare Acquisitions LP (“DRI”), a wholly-owned subsidiary of DRI Healthcare Trust. Originally designed and introduced by Omeros, OMIDRIA is a revolutionary ophthalmic instrument intended for use in cataract and lens replacement procedures.

    Rayner Surgical Inc. received OMIDRIA and its associated business assets from Omeros in December 2021. As per the conditions mentioned in the asset purchase agreement, Omeros is qualified to receive royalties that are determined by OMIDRIA’s net sales. Omeros and DRI entered into a royalty acquisition agreement on September 30, 2022, which brought Omeros a monetary benefit of $125 million.

    This was given in return for a share, restricted by yearly limits, of Omeros’ royalties on global net sales of OMIDRIA payable by Rayner from September 1, 2022, to December 31, 2030. Presently, Omeros and DRI have expanded their royalty purchase agreement, leading to Omeros receiving an upfront payment of $115 million from DRI.

    This entitles DRI to the remaining royalties on U.S. net sales of OMIDRIA, payable between January 1, 2024, and December 31, 2031. Excluding the purchased royalties, DRI holds no claim to Omeros’ assets. As part of the extended agreement, the outstanding balance of $174 million in annual caps payable by Omeros to DRI has been extinguished.

    Furthermore, Omeros stands to receive two milestone payments from DRI, each amounting to a maximum of $27.5 million, scheduled for disbursement in January 2026 and January 2028, contingent on meeting specific OMIDRIA net sales thresholds.